About Jyong Biotech Ltd. Ordinary Shares
https://www.jyongbio.com/Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages.
CEO
Fu-Feng Kuo
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 9
Price Target
About Jyong Biotech Ltd. Ordinary Shares
https://www.jyongbio.com/Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2024 | $0 | $552.5 | $-846.5 | 0% | $-0.01 | $-523.5 |
| Q3-2024 | $0 | $552.5 ▲ | $-846.5 ▼ | 0% | $-0.01 ▼ | $-523.5 ▼ |
| Q2-2024 | $0 | $475.5 | $-663 | 0% | $-0.01 | $-444.5 |
| Q1-2024 | $0 | $475.5 ▼ | $-663 ▲ | 0% | $-0.01 ▲ | $-444.5 ▲ |
| Q4-2023 | $0 | $844 | $-1.33K | 0% | $-0.02 | $-813 |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2024 | $98K | $6.37M | $42.88M | $-36.52M |
| Q3-2024 | $98K ▲ | $6.37M ▼ | $42.88M ▲ | $-36.52M ▼ |
| Q2-2024 | $96K | $6.44M | $41.37M | $-34.93M |
| Q1-2024 | $96K ▼ | $6.44M ▼ | $41.37M ▼ | $-34.93M ▼ |
| Q4-2023 | $177K | $8.25M | $42.32M | $-34.07M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2024 | $-846.5 | $-913K ▼ | $0 | $848K ▲ | $2K ▲ | $-425.5 |
| Q3-2024 | $-846.5 ▼ | $-425.5 ▲ | $0 | $424 ▼ | $0 ▼ | $-425.5 ▲ |
| Q2-2024 | $-663 | $-2.71M ▼ | $0 | $1.14M ▲ | $99K ▲ | $-1.39K |
| Q1-2024 | $-663 ▲ | $-1.39K ▼ | $0 | $571 ▼ | $0 | $-1.39K ▼ |
| Q4-2023 | $-1.33K | $-654.5 | $0 | $657.5 | $0 | $-654.5 |
CEO
Fu-Feng Kuo
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 9